Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.

Pituitary

Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK,

Published: June 2015

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643589	PMC
http://dx.doi.org/10.1007/s11102-014-0628-z	DOI Listing

Publication Analysis

erratum pasireotide

pasireotide lar

lar maintains

maintains inhibition

inhibition igf-1

igf-1 patients

patients acromegaly

acromegaly months

months blinded

blinded extension

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!